New therapeutic agents for chronic hepatitis B

The Lancet Infectious Diseases
Mayur BrahmaniaHarry L A Janssen

Abstract

The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this is rarely achieved with first-line treatment regimens because of an inability to disrupt covalently closed circular DNA and an inadequate host immune response. Therefore, new antiviral agents are needed to target various stages of the hepatitis B virus lifecycle and modulation of the immune system. This Review provides a summary of available regimens with their strengths and limitations, and highlights future therapeutic strategies to target the virus and host immune response. These new agents can hopefully lead to a finite duration of treatment, and provide a functional and durable cure for chronic hepatitis B infection.

References

Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·D R MilichJ L Hughes
Mar 8, 2000·Microbiology and Molecular Biology Reviews : MMBR·C Seeger, W S Mason
Jul 14, 2001·Journal of Hepatology·S PolUNKNOWN Multicenter study group
May 31, 2002·The New England Journal of Medicine·Anna S F Lok
Jul 12, 2002·Nature·Gregory J Hannon
Oct 9, 2002·Journal of Virology·Kiminori KimuraFrancis V Chisari
Apr 2, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Amir Shlomai, Yosef Shaul
Jul 10, 2003·Gastroenterology·Christian KleinChristian Trautwein
Mar 5, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Monika van ZonneveldHarry L A Janssen
Jul 14, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yvette E LatchmanArlene H Sharpe
Sep 17, 2004·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
Jan 11, 2005·Lancet·Harry L A JanssenUNKNOWN Rotterdam Foundation for Liver Research
Jun 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Stephen J StrayAdam Zlotnick
Jul 1, 2005·The New England Journal of Medicine·George K K LauUNKNOWN Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
Feb 28, 2006·Trends in Immunology·Taku Okazaki, Tasuku Honjo
Jan 30, 2007·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Arístides Aguilar BetancourtJ C Aguilar Rubido
Sep 19, 2007·Antimicrobial Agents and Chemotherapy·Anne Marie DoughertyAndrea Cuconati
Nov 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Andreas SchulzeStephan Urban
Dec 7, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Henry Lik-Yuen ChanJoseph Jao-Yiu Sung
Mar 15, 2008·Virus Research·Michael Nassal
Mar 13, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Daniel J TenneyRichard J Colonno
Aug 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F Lok, Brian J McMahon
Oct 13, 2009·Expert Review of Gastroenterology & Hepatology·Antonio Bertoletti, Adam Gehring
Mar 9, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Vincent Wai-Sun WongHenry Lik-Yuen Chan

❮ Previous
Next ❯

Citations

Aug 9, 2016·Journal of Ethnopharmacology·Yan-Hui SunRen Zhang
Mar 7, 2017·Clinical Pharmacology in Drug Development·Norah J Shire
May 4, 2017·Expert Review of Clinical Pharmacology·Syed Abdul BasitRobert Gish
Apr 13, 2018·Genes·Kristie BloomPatrick Arbuthnot
Jan 10, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Masaru EnomotoNorifumi Kawada
Jul 29, 2017·Expert Review of Gastroenterology & Hepatology·Masako OkadaMindie H Nguyen
May 24, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ningning LiuXin Ye
Aug 1, 2019·Current Drug Targets·Bing-Yi ZhangXiao-Ping Yu
Mar 29, 2019·Clinical Epigenetics·Zeina NehmeGeorges Herbein
Feb 26, 2020·Antimicrobial Agents and Chemotherapy·Jan Martin BerkeFrederik Pauwels
Aug 2, 2016·World Journal of Hepatology·Kazuto Tajiri, Yukihiro Shimizu
Aug 17, 2019·World Journal of Clinical Cases·Ya-Li WuXin-Yue Chen
Sep 9, 2017·Tropical Diseases, Travel Medicine and Vaccines·Kittiyod PoovorawanWatcharapong Piyaphanee
Mar 19, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Takashi NishimuraShuhei Nishiguchi
Mar 16, 2019·Digestive Diseases and Sciences·Jordan J Feld, Lisette A P Krassenburg
Sep 25, 2019·Nature Reviews. Gastroenterology & Hepatology·Mala K Maini, Alice R Burton
Apr 22, 2020·International Journal of Pharmaceutics·Ying JiangAjay K Banga
Feb 22, 2021·Bioorganic & Medicinal Chemistry Letters·Scott D KudukGeorge D Hartman
Dec 1, 2019·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yali WuXinyue Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Virology & CRISPR

This feed focuses on the virology of CRISPR and its use in developing CRISPR-Cas systems. Discover the latest research here.

Related Papers

Minerva gastroenterologica e dietologica
Maura Dandri, Joerg Petersen
Liver International : Official Journal of the International Association for the Study of the Liver
Chih-Lin LinJia-Horng Kao
Hepatic Medicine : Evidence and Research
Jacinta A Holmes, Alexander J Thompson
Expert Review of Gastroenterology & Hepatology
Giselle HolnessDouglas T Dieterich
© 2022 Meta ULC. All rights reserved